Diabetes and the Microvasculature of the Bone and Marrow

Le, Teresa; Salas Sanchez, Amanda; Nashawi, Danyah; Kulkarni, Sunidhi; Prisby, Rhonda D.

doi:10.1007/s11914-023-00841-3

Cited by 5 publications

(2 citation statements)

References 116 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This condition is particularly concerning as it markedly increases the likelihood of fractures. Such fractures can lead to high levels of disability, complicating the treatment and rehabilitation process for individuals with diabetes [ 20 , 21 ]. This intersection of diabetes and osteoporosis presents a complex health issue, necessitating more comprehensive and multidisciplinary approaches to management and care.…”

Section: Discussionmentioning

confidence: 99%

Antidiabetic drug administration prevents bone mineral density loss: Evidence from a two-sample Mendelian randomization study

Chen,

Lin,

Chen

et al. 2024

PLoS ONE

View full text Add to dashboard Cite

The aim of this study was to investigate the effect of common antidiabetic drugs on BMD by two-sample Mendelian randomization (MR). The single nucleotide polymorphisms that were strongly associated with insulin, metformin, rosiglitazone and gliclazide were extracted as instrumental variables (IVs) for MR analysis. The inverse variance weighted (IVW) method was used as the primary MR method to assess the causal effect of antidiabetic drugs on BMD, and other MR methods, including Weighted median, MR Egger and Weighted mode, were used for complementary analysis. Reliability and stability were assessed by the leave-one-out test. In the present work, IVW estimation of the causal effect of insulin on heel BMD demonstrated that there was a null effect of insulin on heel BMD (β = 0.765; se = 0.971; P = 0.430), while metformin treatment had a positive effect on heel BMD (β = 1.414; se = 0.460; P = 2.118*10−3). The causal relationship between rosiglitazone and heel BMD analysed by IVW suggested that there was a null effect of rosiglitazone on heel BMD (β = -0.526; se = 1.744; P = 0.763), but the causal effect of gliclazide on heel BMD evaluated by IVW demonstrated that there was a positive effect of gliclazide on heel BMD (β = 2.671; se = 1.340; P = 0.046). In summary, the present work showed that metformin and gliclazide have a role in reducing BMD loss in patients with diabetes and are recommended for BMD loss prevention in diabetes.

show abstract

Section: Discussionmentioning

confidence: 99%

Antidiabetic drug administration prevents bone mineral density loss: Evidence from a two-sample Mendelian randomization study

Chen,

Lin,

Chen

et al. 2024

PLoS ONE

View full text Add to dashboard Cite

show abstract

“…This is because the pathological circumstance of diabetes mellitus is very complicated, where biochemical disturbance, excessive inflammation, and high expression of reactive oxide species are all involved [ [10] , [11] , [12] , [13] , [14] ]. The microenvironment of bone marrow is also changed, which hampers the formation of new bones containing small blood vessels [ 14 , 15 ]. Therefore, the bone healing under diabetes conditions is difficult, and hence the implanted biomaterials designed with special functions are urgently needed.…”

Section: Introductionmentioning

confidence: 99%

A 3D-printed scaffold composed of Alg/HA/SIS for the treatment of diabetic bone defects

Tan,

Chen,

et al. 2024

Journal of Orthopaedic Translation

View full text Add to dashboard Cite

Reduced Graphene Oxide-Substituted Nanohydroxyapatite: Rejuvenating Bone–Nerve Crosstalk with Electrical Cues in a Fragility Fracture Rat Model under Hyperglycemia

Srivastava,

Qayoom,

Kumar

2024

ACS Appl. Mater. Interfaces

View full text Add to dashboard Cite

Diabetes has currently acquired the status of epidemic worldwide, and among its various pathological consequences like retinopathy and nephropathy, bone fragility fractures from diabetic osteopathy occurs in later stages and is equally destructive. Chronic hyperglycemia culminates into deteriorating microvasculature and quality of bone, making it prone to fractures. Among these, hip fractures are most common, especially in older diabetic patients apart from underlying neuropathy. Our study is an attempt to ameliorate hip fragility fracture and nerve trauma with electrical stimulation as an interface in a chronic diabetic rat model. We have fabricated reduced graphene oxide-substituted hydroxyapatite as an electroactive bone substitute and incorporated it into chitosan gelatin cryogels. The in situ reduction of graphene oxide during sintering of hydroxyapatite imparts higher potential to the fabricated composite in dealing with problem at question. The cryogels depicted optimum in vitro biocompatibility and enhanced mineralization after ectopic subcutaneous implantation in rats. The therapeutic potency of composite cryogels was evaluated in a hip fracture model with compression to the sciatic nerve in diabetic rats, mimicking the severe clinical trauma. The presence of cryogels in the femoral neck canal coupled with electrical stimulation and biochemical factors significantly improved bone regeneration in diabetic rats as depicted with microcomputed tomography analysis and histology images. The application of electrical stimulation also ameliorated the nerve trauma observed with 70% improvement in electrophysiological parameters such as the compound muscle action potential with combinatorial therapy. We therefore report the successful implication of a multitarget therapy in a chronic diabetic rat model unraveling the bone−nerve crosstalk with electroactive smart cryogels.

show abstract

Diabetes and the Microvasculature of the Bone and Marrow

Cited by 5 publications

References 116 publications

Antidiabetic drug administration prevents bone mineral density loss: Evidence from a two-sample Mendelian randomization study

Antidiabetic drug administration prevents bone mineral density loss: Evidence from a two-sample Mendelian randomization study

A 3D-printed scaffold composed of Alg/HA/SIS for the treatment of diabetic bone defects

Reduced Graphene Oxide-Substituted Nanohydroxyapatite: Rejuvenating Bone–Nerve Crosstalk with Electrical Cues in a Fragility Fracture Rat Model under Hyperglycemia

Contact Info

Product

Resources

About